Toshiba’s Cardio Prospective helps reduce patient radiation dose by up to 80 percent during coronary CTA exams by using a helical acquisition technique to provide one continuous image instead of multiple images produced by the current step-and-shoot technique.
February 11, 2008 – Medrad Inc. today said it entered into a definitive merger agreement to acquire Possis Medical Inc., which in combination will offer a broader, more comprehensive suite of products to the cardiovascular intervention field.
February 11, 2008 - Having a heart attack is apparently not sufficient reason for most people to change to a heart-healthy diet, a new study finds. "We found that diet quality is poor after a coronary heart disease event," said study author Yunsheng Ma, M.D., an assistant professor of medicine at the University of Massachusetts Medical School, in Worcester.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The Artida is reportedly the first ultrasound system with the ability to track and display myocardial motion and 3D volumes in 3D images. Two and 3D wall motion tracking features allow the user to obtain angle-independent, quantitative and regional information about myocardial contraction.
February 11, 2008 – A new minimally invasive vascular occlusion device designed to close a patent ductus arteriosus (PDA) received European CE Mark approval.
Toshiba's Vantage Titan MRI is designed to capture higher resolution heart images, while capturing deeper imaging of the anatomy. This is possible due to the center eight elements of the cardiac coils being smaller and the outer eight elements of the cardiac coils being larger on the Vantage Titan according to Toshiba.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
February 11, 2008 - The first patient has enrolled in the PROENCY (PROMUS, Endeavor and Cypher) European registry ...
February 8, 2008 - CryoLife Inc. received 510(k) clearance from the FDA for its CryoValve SG pulmonary human heart valve processed with the company’s proprietary SynerGraft technology, providing a valve replacement option for children born with heart defects or for replacement surgery.
February 8, 2008 - The FDA granted Volcano Corp. 510(k) clearance for its s5-Revo and s5-FFR (fractional flow reserve) options, allowing physicians access phased Array IVUS, Rotational IVUS and integrated FFR on the same integrated IVUS platform.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
CryoLife Inc.'s CryoValve SG pulmonary human heart valve is processed with the company’s proprietary SynerGraft technology, providing a valve replacement option for children born with heart defects or for replacement surgery.
February 8, 2008 – CryoLife Inc. said it received FDA 510(k) clearance for its CryoValve SG pulmonary human heart valve ...
February 8, 2008 - The FDA granted Volcano Corp. 510(k) clearance for its s5-Revo and s5-FFR (fractional flow reserve) options, allowing physicians access phased Array IVUS, Rotational IVUS and integrated FFR on the same integrated IVUS platform.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
February 8, 2008 - Emageon received first place in the “Best in KLAS” Top 20 Report for the Cardiology PACS nomination ...
February 7, 2008 - Volcano Corp. said the FDA cleared the s5-Revo and s5-FFR (fractional flow reserve) options, enabling ...
Emageon's HeartSuite offers cardiovascular information management, hemodynamic monitoring, advanced visualization and content management. Emageon’s architecture combines HeartSuite with radiology and other medical specialties designed to offer a comprehensive patient–centric view of the visual medical record. One suite of integrated, enterprise cardiology tools includes: